Business Description
AN2 Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0373261058
Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8785.39 | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -78.5 | |||||
3-Year EPS without NRI Growth Rate | -41.5 | |||||
3-Year FCF Growth Rate | -80.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.19 | |||||
9-Day RSI | 55.35 | |||||
14-Day RSI | 50.91 | |||||
6-1 Month Momentum % | -89.86 | |||||
12-1 Month Momentum % | -74.37 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.91 | |||||
Quick Ratio | 10.91 | |||||
Cash Ratio | 10.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.4 | |||||
Shareholder Yield % | -131.75 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -60.62 | |||||
ROA % | -54.67 | |||||
ROIC % | -488.32 | |||||
ROCE % | -66.01 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.58 | |||||
Price-to-Tangible-Book | 0.58 | |||||
EV-to-EBIT | 0.43 | |||||
EV-to-EBITDA | 0.43 | |||||
EV-to-FCF | 0.52 | |||||
Price-to-Net-Current-Asset-Value | 0.61 | |||||
Price-to-Net-Cash | 0.62 | |||||
Earnings Yield (Greenblatt) % | 232.56 | |||||
FCF Yield % | -92.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AN2 Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -2.59 | ||
Beta | 0 | ||
Volatility % | 134.15 | ||
14-Day RSI | 50.91 | ||
14-Day ATR ($) | 0.113543 | ||
20-Day SMA ($) | 2.065 | ||
12-1 Month Momentum % | -74.37 | ||
52-Week Range ($) | 1.91 - 22.22 | ||
Shares Outstanding (Mil) | 29.83 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
AN2 Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
AN2 Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
AN2 Therapeutics Inc Frequently Asked Questions
What is AN2 Therapeutics Inc(ANTX)'s stock price today?
The current price of ANTX is $2.15. The 52 week high of ANTX is $22.22 and 52 week low is $1.91.
When is next earnings date of AN2 Therapeutics Inc(ANTX)?
The next earnings date of AN2 Therapeutics Inc(ANTX) is 2024-08-09 Est..
Does AN2 Therapeutics Inc(ANTX) pay dividends? If so, how much?
AN2 Therapeutics Inc(ANTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |